Suppr超能文献

非酒精性脂肪性肝病与 2 型糖尿病患者糖尿病微血管并发症的发生:一项前瞻性队列研究。

Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study.

机构信息

Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Student Research committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Front Endocrinol (Lausanne). 2023 Jun 5;14:1147458. doi: 10.3389/fendo.2023.1147458. eCollection 2023.

Abstract

OBJECTIVE

To investigate the association between non-alcoholic fatty liver disease (NAFLD) and liver enzymes with the incidence of microvascular complications (neuropathy, retinopathy, and nephropathy) in a cohort of Iranian patients with type 2 diabetes.

METHODS

For a total population of 3123 patients with type 2 diabetes, a prospective study was designed for 1215 patients with NAFLD and 1908 gender and age-matched control patients without NAFLD. The two groups were followed for a median duration of 5 years for the incidence of microvascular complications. The association between having NAFLD, the level of liver enzymes, aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4) value, and the incidence risk of diabetic retinopathy, neuropathy, and nephropathy were assessed through logistic regression analysis.

RESULTS

NAFLD was found to be associated with incidence of diabetic neuropathy and nephropathy (Odds ratio: 1.338 (95% confidence interval: 1.091-1.640) and 1.333 (1.007-1.764), respectively). Alkaline-phosphatase enzyme was found to be associated with higher risks of diabetic neuropathy and nephropathy ((Risk estimate: 1.002 (95% CI: 1.001-1.003) and 1.002 (1.001-1.004), respectively)). Moreover, gamma-glutamyl transferase was associated with a higher risk of diabetic nephropathy (1.006 (1.002-1.009). Aspartate aminotransferase and alanine aminotransferase were inversely associated with the risk of diabetic retinopathy (0.989 (0.979-0.998) and 0.990 (0.983-0.996), respectively). Furthermore, ARPI_T (1), ARPI_T (2), and ARPI_T (3) were shown to be associated with NAFLD (1.440 (1.061-1.954), 1.589 (1.163-2.171), and 2.673 (1.925, 3.710), respectively). However, FIB-4 score was not significantly associated with risk of microvascular complications.

CONCLUSION

Despite the benign nature of NAFLD, patients with type 2 diabetes should be always assessed for NAFLD to ensure early diagnosis and entry into proper medical care. Regular screenings of microvascular complications of diabetes is also suggested for these patients.

摘要

目的

探讨非酒精性脂肪性肝病(NAFLD)与肝酶与伊朗 2 型糖尿病患者微血管并发症(神经病变、视网膜病变和肾病)发生率之间的关系。

方法

对 3123 例 2 型糖尿病患者进行总体人群研究,对 1215 例有 NAFLD 和 1908 例性别和年龄匹配的无 NAFLD 对照组患者进行前瞻性研究。两组患者中位随访 5 年,观察微血管并发症的发生率。通过 logistic 回归分析评估有 NAFLD、肝酶水平、天门冬氨酸氨基转移酶与血小板比值指数(APRI)、纤维化-4(FIB-4)值与糖尿病视网膜病变、神经病变和肾病发病风险之间的关系。

结果

NAFLD 与糖尿病神经病变和肾病的发生有关(比值比:1.338(95%置信区间:1.091-1.640)和 1.333(1.007-1.764))。碱性磷酸酶与糖尿病神经病变和肾病的风险升高有关(风险估计值:1.002(95%CI:1.001-1.003)和 1.002(1.001-1.004))。此外,γ-谷氨酰转移酶与糖尿病肾病的风险升高有关(1.006(1.002-1.009))。天门冬氨酸氨基转移酶和丙氨酸氨基转移酶与糖尿病视网膜病变的风险呈负相关(0.989(0.979-0.998)和 0.990(0.983-0.996))。此外,ARPI_T(1)、ARPI_T(2)和 ARPI_T(3)与 NAFLD 相关(1.440(1.061-1.954)、1.589(1.163-2.171)和 2.673(1.925,3.710))。然而,FIB-4 评分与微血管并发症风险无显著相关性。

结论

尽管 NAFLD 为良性疾病,但 2 型糖尿病患者仍应始终评估是否存在 NAFLD,以确保早期诊断和适当的医疗护理。建议对这些患者进行糖尿病微血管并发症的常规筛查。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验